Browsing Tag
Cytokinetics
5 posts
FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success
FDA approves Cytokinetics’ aficamten for obstructive HCM. Find out what this means for cardiologists, patients, and rival Camzyos as MYQORZO prepares to launch.
Thryv Therapeutics secures FDA IND clearance to launch first potential drug for Long QT syndrome
Thryv Therapeutics gains FDA IND clearance for THRV-1268 in Long QT Syndrome, aiming to pioneer the first disease-modifying therapy for this rare disorder.
Cytokinetics stock skyrockets 40% as ESC 2025 data positions aficamten to challenge beta-blockers in HCM
Cytokinetics shares surged 40% after new ESC 2025 data showed aficamten's superiority to metoprolol in HCM. Is FDA approval now inevitable?
Sanofi strengthens cardiovascular portfolio with Aficamten rights in Greater China
Cytokinetics, Incorporated (NASDAQ: CYTK) saw its shares climb by 4.8% after announcing a landmark agreement with Sanofi (NASDAQ:…
Cytokinetics bags FDA breakthrough therapy status for aficamten in oHCM
Cytokinetics has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for aficamten for the…